Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,653 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (718)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00002970 | 506U78 in Treating Patients With Refractory Hematologic Cancer | completed | Phase 2 | 148 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT01095926 | Pharmacokinetic Study of Doxorubicin in Children With Cancer(Doxo) | completed | Phase 2 | 101 | University Hospital MuensterOTHER | 4 | Jun 28, 2013 | clinicaltrials |
| NCT00195000 | Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS | completed | Phase 2 | 43 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00089349 | Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00358644 | Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML) | completed | Phase 2 | 55 | Eisai Inc.INDUSTRY | 1 | May 20, 2013 | clinicaltrials |
| NCT00027872 | Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 2 | 125 | National Cancer Institute (NCI)NIH | 1 | Mar 25, 2013 | clinicaltrials |
| NCT00412243 | Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients | completed | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 12, 2013 | clinicaltrials |
| NCT00797758 | Reduction of Cord Blood Transplantation Toxicity in Patients With Acute Myeloid Leukemia(MINICORD) | completed | Phase 2 | 76 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 8, 2013 | clinicaltrials |
| NCT00968071 | Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome | completed | Phase 2 | 71 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 8, 2013 | clinicaltrials |
| NCT00398983 | Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML) | completed | Phase 2 / Phase 3 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2013 | clinicaltrials |
| NCT00651781 | Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 40 | PETHEMA FoundationOTHER | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00005811 | Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment | completed | Phase 2 | 77 | National Cancer Institute (NCI)NIH | 1 | Feb 21, 2013 | clinicaltrials |
| NCT00037596 | Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia | completed | Phase 2 | — | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Feb 13, 2013 | clinicaltrials |
| NCT00520208 | Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL(STAR-1) | completed | Phase 2 | 15 | CytRxINDUSTRY | 1 | Feb 13, 2013 | clinicaltrials |
| NCT00005942 | Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy | completed | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00084916 | CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00093418 | S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia | completed | Phase 2 | 296 | National Cancer Institute (NCI)NIH | 1 | Jan 15, 2013 | clinicaltrials |
| NCT00004918 | Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00915252 | Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)(AML-AZA) | completed | Phase 2 | 214 | University Hospital MuensterOTHER | 1 | Dec 17, 2012 | clinicaltrials |
| NCT00031655 | Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission | completed | Phase 2 | 30 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 1 | Dec 7, 2012 | clinicaltrials |
| NCT00762632 | Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 40 | Technical University of MunichOTHER | 1 | Aug 8, 2012 | clinicaltrials |
| NCT00088218 | Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS). | completed | Phase 2 | 95 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00382590 | Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients | completed | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00418951 | Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections | completed | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT01031498 | Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting | completed | Phase 2 | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00038831 | Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS | completed | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
| NCT00569010 | Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
| NCT00773149 | Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia(Campath) | completed | Phase 1 / Phase 2 | 12 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 26, 2012 | clinicaltrials |
| NCT00780598 | Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML(OPAL) | completed | Phase 2 | 76 | Chroma TherapeuticsINDUSTRY | 3 | Jun 28, 2012 | clinicaltrials |
| NCT00326170 | Phase II 5-Azacytidine Plus VPA Plus ATRA | completed | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2012 | clinicaltrials |
| NCT00071006 | AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS) | completed | Phase 2 | 12 | PfizerINDUSTRY | 1 | Jun 8, 2012 | clinicaltrials |
| NCT00823316 | Safety and Efficacy Study of Umbilical Cord Blood-Drived Mesenchymal Stem Cells to Promote Engraftment of Unrelated Hematopoietic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 10 | Medipost Co Ltd.INDUSTRY | 1 | Apr 23, 2012 | clinicaltrials |
| NCT00719836 | A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies | completed | Phase 1 / Phase 2 | 76 | S*BIOINDUSTRY | 1 | Apr 20, 2012 | clinicaltrials |
| NCT01170598 | Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy | completed | Phase 2 | 35 | Toronto Rehabilitation InstituteOTHER | 1 | Apr 20, 2012 | clinicaltrials |
| NCT00270881 | Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 33 | Keio UniversityOTHER | 1 | Apr 6, 2012 | clinicaltrials |
| NCT00890656 | Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage | completed | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 20, 2012 | clinicaltrials |
| NCT00764231 | A Study of a Home-based Exercise Intervention for Patients With Acute Myeloid Leukaemia (AML) | completed | Phase 2 | 40 | Toronto Rehabilitation InstituteOTHER | 1 | Feb 8, 2012 | clinicaltrials |
| NCT00144677 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00144703 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation | completed | Phase 2 | 55 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00795548 | Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation | completed | Phase 2 | 30 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Jan 23, 2012 | clinicaltrials |
| NCT00088231 | PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP | completed | Phase 1 / Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 20, 2012 | clinicaltrials |
| NCT00289562 | Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 20 | BioCryst PharmaceuticalsINDUSTRY | 1 | Jan 20, 2012 | clinicaltrials |
| NCT00723346 | Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia(GRASPALL) | completed | Phase 1 / Phase 2 | 25 | ERYtech PharmaINDUSTRY | 1 | Jan 11, 2012 | clinicaltrials |
| NCT00388531 | Depocyte in the Treatment of CNS Relapse in Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma | completed | Phase 2 | 10 | PETHEMA FoundationOTHER | 1 | Sep 19, 2011 | clinicaltrials |
| NCT00760084 | Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 10 | Eisai Inc.INDUSTRY | 1 | Aug 8, 2011 | clinicaltrials |
| NCT01385891 | Clove In The Treatment Of Relapsed Or Resistant Acute Leukemia In Children(CLOVE) | completed | Phase 2 / Phase 3 | 40 | Istituto Giannina GasliniOTHER | 1 | Jul 8, 2011 | clinicaltrials |
| NCT00339196 | 5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS | completed | Phase 2 | 25 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 9, 2011 | clinicaltrials |
| NCT00400673 | A Risk-Oriented Therapeutic Strategy for Adult Acute Myelogenous Leukemia | completed | Phase 2 | 581 | Northern Italy Leukemia GroupOTHER | 1 | Apr 1, 2011 | clinicaltrials |
| NCT00136448 | High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Jul 2, 2013source: clinicaltrials